跳至主要内容
临床试验/NCT06266975
NCT06266975尚未招募不适用

Chronic Kidney Disease Patient in Chronic Myloied Leukemia

Sahar Mohammed Gad0 个研究点目标入组 40 人开始时间: 2024年2月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
40
主要终点
Chronic Kidney Disease Patient in Chronic Myloied Leukemia

研究概览

简要总结

To study the Prevalence ,Characteristics and outcome of CKD in patiants with chronic myeloid leukemia .

详细描述

  • Chronic myeloid leukemia (CML) is a cancer of bone marrow that leads to an increased number of white blood cells. CML is more prevalent in the elderly and is characterized by weight loss, tiredness, shortness of breath, excessive sweating, bone pain, and frequent infections. [1] According to the American Cancer Society's estimates, CML represents 15% of all new leukemia cases.[2] The global burden of disease (GBD) study 2015 revealed that leukemia was under the top ten leading causes of death globally.[3] However, the latest GBD study found a decrease in the age-standardized incidence rate and the death rate from 1990-2017.[4] This dramatic improvement in the overall survival and health-related quality of life among CML patients was attributed to the impact of new therapeutic strategies. Tyrosine kinase inhibitors (TKIs), particularly imatinib, emerged as a potential therapeutic agent for the treatment of CML, reducing epidemiological burden (incidence rate), and improve quality of life.[5]
  • The definition and classification of chronic kidney disease (CKD) have evolved over time, but current international guidelines define this condition as decreased kidney function shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1•73 m2, or markers of kidney damage, or both, of at least 3 months duration, regardless of the underlying cause[6] Diagnosis is commonly made after chance findings from screening tests (urinary dipstick or blood tests), or when symptoms become severe. The best available indicator of overall kidney function is GFR, which is measured either via exogenous markers (eg, DTPA, iohexol), or estimated using equations. Presence of proteinuria is associated with increased risk of progression of CKD and death. Presence of proteinuria is associated with increased risk of progression of CKD and death.[7,8] Kidney biopsy samples can show definitive evidence of CKD, through common changes such as glomerular sclerosis, tubular atrophy, and interstitial fibrosis. Complications include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell survival and iron deficiency; and mineral bone disease caused by disturbed vitamin D, calcium, and phosphate metabolism.[9

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1_ Chronic myloid leukemia patiants who diagonised by biopsy , 2_ CBC.
  • Exclusion : 1_pts known to have CKD before diagnosed of CML. 2- known Diabetic pts 3-imaging suggestive CKD etiology rather than CML effect eg.PKD,renal stones,chronic pyelonephritis

排除标准

  • 未提供

结局指标

主要结局

Chronic Kidney Disease Patient in Chronic Myloied Leukemia

时间窗: basline

Using Non Invasive or invasive Methods and correlation between lab and radiological methods to find and a relation between CML and CKD and outcome.

次要结局

未报告次要终点

研究者

发起方
Sahar Mohammed Gad
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Sahar Mohammed Gad

doctor

Assiut University

相似试验